October 27, 2026

Endometrial cancer drug cuts progression or death risk 41%

FDA grants Priority Review following improved survival versus chemotherapy in phase 3 trial.

MDSpire News

October 27, 2026

FDA expands talazoparib use in prostate cancer

The combination with enzalutamide reduced the risk of radiographic progression or death by 52% .

MDSpire News

October 23, 2026

FDA raises TMB threshold for pembrolizumab

Traditional approval narrows eligibility for previously treated solid tumors after efficacy was not confirmed at lower biomarker levels.

MDSpire News

October 19, 2026

FDA approves dostarlimab for advanced rectal cancer

The accelerated approval adds an immunotherapy option for patients with MSI-H/dMMR stage II/III disease.

MDSpire News

October 14, 2026

Skin odor signatures may shift with age

Investigators linked distinct odor patterns to life stage, sex, and skin microbes, while limited longitudinal evidence leaves their clinical utility uncertain.

MDSpire News

October 09, 2026

FDA approves atezolizumab for dMMR colon cancer

In the phase 3 ATOMIC trial, adjuvant atezolizumab plus chemotherapy halved the risk of recurrence or death in stage 3 patients.

MDSpire News

October 09, 2026

Medical debt linked to higher late-stage cancer rates

Lung cancer showed the strongest absolute association, while prostate and breast cancer findings diverged from the broader pattern.

MDSpire News

October 07, 2026

FDA grants Temab-A dual Breakthrough status

The designations cover refractory metastatic CRC and previously treated c-Met–expressing NSCLC.

MDSpire News

September 30, 2026

Misleading AI summaries may alter recall

Participants exposed to inaccurate postevent summaries were less likely to correctly remember key details from videos they had previously watched.

MDSpire News

September 30, 2026

Vitamin D may ease cancer treatment skin toxicity

Most patients reported symptom relief within 10 days, while 73% continued anticancer therapy without interruption.

MDSpire News